Novartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buybackCNBC • 07/18/23
Novartis Puts Up Its Biggest Earnings Growth In Two Years; Shares PopInvestors Business Daily • 07/18/23
Novartis Stock Climbs. It's All About a Hike in Outlook and $15 Billion Share Buyback.Barrons • 07/18/23
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with NovartisPRNewsWire • 07/18/23
Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off[1],[2]GlobeNewsWire • 07/18/23
Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlookGlobeNewsWire • 07/07/23
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To AcquireInvestors Business Daily • 07/05/23
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million UpfrontSeeking Alpha • 07/02/23
Bausch + Lomb Buys Novartis Drugs for $1.75 Billion Expanding Eye Care PortfolioInvestopedia • 06/30/23
Bausch + Lomb to acquire dry eye treatment from Novartis in potential $2.5B dealProactive Investors • 06/30/23